FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Cited by (238)

Items 101–200 of 238

1. Protective effects of yangonin from an edible botanical Kava against lithocholic acid‐induced cholestasis and hepatotoxicity
   Yulong Kong, Xiaoguang Gao, Chang-Yuan Wang, Chenqing Ning, Ke-Xin Liu, Zhi-Hao Liu, Hui-Jun Sun, Xiaodong Ma, P. Sun, Q. Meng · 2018 · European Journal of Pharmacology
2. Farnesoid X receptor promotes renal ischaemia‐reperfusion injury by inducing tubular epithelial cell apoptosis
   Yao Xu, Dawei Li, Jiajin Wu, Minfang Zhang, Xinghua Shao, Longmei Xu, Lumin Tang, Minyan Zhu, Zhaohui Ni, Ming Zhang et al. · 2021 · Cell Proliferation
3. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
   Yi‐Hsun Chen, Wei‐Kai Wu, Ming‐Shiang Wu · 2020 · International Journal of Molecular Sciences
4. Phytosterols Synergize With Endotoxin to Augment Inflammation in Kupffer Cells but Alone Have Limited Direct Effect on Hepatocytes
   Gregory J. Guthrie, Bryan C. Tackett, Barbara Stoll, Camilia Rivera Martin, Oluyinka O. Olutoye, Douglas G. Burrin · 2017 · Journal of Parenteral and Enteral Nutrition
5. FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
   Benedikt Simbrunner, Benedikt Hofer, Philipp Schwabl, Kerstin Zinober, Oleksandr Petrenko, Claudia Daniela Fuchs, Georg Semmler, Rodrig Marculescu, Mattias Mandorfer, Christian Datz et al. · 2024 · Hepatology International
6. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease
   Luisa Vonghia, Mikhaïl A. Van Herck, Jonas Weyler, Sven Francque · 2019 · Frontiers in Immunology
7. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
   Yuki Tsuji, Kosuke Kaji, Mitsuteru Kitade, Daisuke Kaya, Koh Kitagawa, Takahiro Ozutsumi, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki et al. · 2020 · Microorganisms
8. Steroidal or non-steroidal FXR agonists – Is that the question?
   Len Verbeke, Frederik Nevens, Wim Laleman · 2017 · Journal of Hepatology
9. Phenotyping the Chemical Communications of the Intestinal Microbiota and the Host: Secondary Bile Acids as Postbiotics
   Ginevra Urbani, Elena Rondini, Eleonora Distrutti, Silvia Marchianò, Michele Biagioli, Stefano Fiorucci · 2025 · Cells
10. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3
    Yuanyuan Fan, Wen Ding, Cheng Zhang, Lin Fu, De‐Xiang Xu, Xi Chen · 2019 · International Immunopharmacology
11. Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
    Benedikt Simbrunner, Rafael Paternostro, Thomas Reiberger, Michael Trauner · 2025 · Hepatology
12. Interaction of inflammation and portal hypertension in cirrhosis progression
    Dalila Costa, Jonel Trebicka, Cristina Ripoll, Richard Moreau, Rajiv Jalan, Thomas Reiberger · 2025 · Nature Reviews Gastroenterology & Hepatology
13. Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms
    Heming Ma, Xu Liu, Mingyuan Zhang, Junqi Niu · 2021 · Molecular Biology Reports
14. Palladium‐Catalyzed Base‐Promoted Arylation of Unactivated C(sp3)–H Bonds by Aryl Iodides: A Practical Approach To Synthesize β‐Aryl Carboxylic Acid Derivatives
    Quan Gou, Gang Liu, Lanxiu Zhou, Suiyun Chen, Jun Qin · 2017 · European Journal of Organic Chemistry
15. Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis
    Rasha A. Tawfiq, Noha Nagah Nassar, Olfat Ali Hammam, Rasha Mosa Allam, Mohamed Mohey Elmazar, Dalaal M. Abdallah, Yasmeen M. Attia · 2022 · Chemico-Biological Interactions
16. The Role of Chemokine Receptors in Renal Fibrosis
    Fenglei Wu, Chi Chin Sun, Lu Jianquan · 2020 · Reviews of physiology, biochemistry and pharmacology
17. Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis
    Dipankar Bhattacharya, Christine Becker, Benjamin P. Readhead, Nicolas Goossens, Jacqueline L. Buros, Maria Isabel Fiel, Leslie P. Cousens, Björn Magnusson, Anna Backmark, Ryan Hicks et al. · 2021 · Scientific Reports
18. Butylparaben induces glycolipid metabolic disorders in mice via disruption of gut microbiota and FXR signaling
    Hai‐Ning Du, Lili Cui, Xinyi Zhao, Ziteng Yu, Tianyue He, Boya Zhang, Xingpei Fan, Meimei Zhao, Ruijiao Zhu, Ziyi Zhang et al. · 2024 · Journal of Hazardous Materials
19. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis
    Cho‐Rong Bae, Jun Hino, Hiroshi Hosoda, Mikiya Miyazato, Kenji Kangawa · 2018 · Life Sciences
20. Andrographolide derivative as STAT3 inhibitor that protects acute liver damage in mice
    Shaoru Chen, Li Feng, Mo‐Yu Ding, Decai Wang, Qi Zhao, Yitao Wang, Guo‐Chun Zhou, Ying Wang · 2018 · Bioorganic & Medicinal Chemistry
21. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation
    Tian Qin, Jingyuan Fu, Henkjan J. Verkade · 2020 · Human Genetics
22. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis
    Vlad Ratziu · 2021 · Clinical Liver Disease
23. Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway
    Yu-Lien Tsai, Chih-Wei Liu, Chien-Fu Hsu, Chia‐Chang Huang, Ming-Wei Lin, Shiang‐Fen Huang, Tzu‐Hao Li, Kuei‐Chuan Lee, Yun‐Cheng Hsieh, Yingying Yang et al. · 2020 · Clinical Science
24. Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation
    Rachel E. Etherington, Benjamin John Minford Millar, Barbara A. Innes, David E. Jones, John Andrew Kirby, John G. Brain · 2019 · FASEB BioAdvances
25. Yangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner
    Renchao Dong, Junqiao Wang, Xiaoguang Gao, Changyuan Wang, Kexin Liu, Jingjing Wu, Zhihao Liu, Huijun Sun, Xiaodong Ma, Qiang Meng · 2019 · European Journal of Pharmacology
26. The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure
    Anna Maria Czarnecka, Krzysztof Milewski, Jan Albrecht, Magdalena Zielińska · 2020 · International Journal of Molecular Sciences
27. Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis
    Azizsoltani, Arezou, Niknam, Bahare, Taghizadeh-Teymorloei, Mohammad, Ghoodjani, Erfan, Dianat-Moghadam, Hassan, Alizadeh, Effat · 2025 · Biomedicine & Pharmacotherapy
28. Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice
    Elena Góméz, J.L. Montero, E. Molina, Luisa Garcı́a-Buey, Marta Casado, Javier Fuentes, Miguel Ángel Simón, Álvaro Díaz‐González, Francisco Jorquera, Rosa Maria Morillas et al. · 2024 · Alimentary Pharmacology & Therapeutics
29. Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression
    Yuly Paulin Mendoza, Sofia Tsouka, Georg Semmler, Patcharamon Seubnooch, Katrin Freiburghaus, Mattias Mandorfer, Jaime Bosch, Mojgan Masoodi, Annalisa Berzigotti · 2024 · Journal of Hepatology
30. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice
    Junxiao Li, Chuhe Liu, ZhenYu Zhou, Baokai Dou, Jin-Wen Huang, Leilei Huang, Pei-Yong Zheng, Shengjie Fan, Cheng Huang · 2021 · Phytotherapy Research
31. Asiatic acid alleviates liver fibrosis via multiple signaling pathways based on integrated network pharmacology and lipidomics
    Yong Li, Xu-Lin He, Liping Zhou, Xiao-Zhong Huang, Shan Li, Su Guan, Jing Li, Lei Zhang · 2022 · European Journal of Pharmacology
32. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation
    Xiaohui Wang, Ting Fu, Junqiao Wang, Changyuan Wang, Kexin Liu, Jingjing Wu, Huijun Sun, Xiaodong Ma, Pengyuan Sun, Qiang Meng · 2019 · International Immunopharmacology
33. A Review of Liver Fibrosis and Emerging Therapies
    Rooshi Nathwani, Benjamin Harvey Mullish, David Kockerling, Roberta Forlano, Pinelopi Manousou, Ameet Dhar · 2020 · European Medical Journal
34. New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target
    Yunqi Xing, Yanghao Ou, Yujie Wang, Luming Hou, Junfeng Zhu · 2025 · Biochemical Pharmacology
35. Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets
    Mariana Michelle Ramírez-Mejía, Guadalupe Ponciano‐Rodríguez, Nahúm Méndez‐Sánchez · 2025 · Archives of Medical Research
36. Diminished Tubule Epithelial Farnesoid X Receptor Expression Exacerbates Inflammation and Fibrosis Response in Aged Rat Kidney
    Sugyeong Ha, Yejin Yang, Jeong Won Kim, Minjung Son, Doyeon Kim, Mi‐Jeong Kim, Dong‐Soon Im, Hae Young Chung, Ki Wung Chung · 2022 · The Journals of Gerontology Series A
37. Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes
    Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Ivanivna Kamyshna, Ihor Vorobets, Iryna Halabitska, Oleksandr Kamyshnyi · 2024 · Viruses
38. Novel regulators of hepatic macrophages in liver fibrosis
    Tang, Xiangjun, Bai, Meiwen, Du, Xianhong, Wang, Hong, Liu, Meifang, Fu, Xiaoyan, Zhang, Hongxia, Liang, Shujuan, Wang, Liyuan · 2025 · Frontiers in Immunology
39. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
    Eric Kalo, Scott A. Read, Golo Ahlenstiel · 2021 · Livers
40. The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury
    Andrea Ferrigno, Laura Giuseppina Di Pasqua, Clarissa Berardo, Veronica Siciliano, Vittoria Rizzo, Luciano Adorini, Plinio Richelmi, Mariapia Vairetti · 2018 · PLoS ONE
41. Inflammation Drives MicroRNAs to Limit Hepatocyte Bile Acid Transport in Murine Biliary Atresia
    Mark Azeltine, Emily J. Chavez, Kelsey Marie Nemec, Joseph M. Bednarek, Rengasamy Asokan, Natarajan Balasubramaniyan, Carlos Zgheib, Cara L. Mack, Jonathan P. Roach · 2020 · Journal of Surgical Research
42. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
    Vinka Rupčić Rubin, Kristina Bojanić, Martina Smolić, Jurica Rubin, Ashraf Abdou Tabll, Robert Smolić · 2021 · Journal of Clinical and Translational Hepatology
43. Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition
    Rumei Li, Milaine V. Hovingh, Martijn Koehorst, Pim de Blaauw, Henkjan J. Verkade, Jan Freark de Boer, Folkert Kuipers · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
44. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis
    Naotaka Shimozato, Tadashi Namisaki, Kosuke Kaji, Mitsuteru Kitade, Yasushi Okura, Shinya Sato, Kei Moriya, Kenichiro Seki, Hideto Kawaratani, Hiroaki Takaya et al. · 2019 · Hepatology Research
45. Farnesoid X receptor and bile acids regulate vitamin A storage
    A. Saeed, Jing Yang, J. Heegsma, A. Groen, S. V. van Mil, C. Paulusma, Lu Zhou, Bang-Mao Wang, K. Faber · 2019 · Scientific Reports
46. Genomics and metabolomics of early-stage thioacetamide-induced liver injury: An interspecies study between guinea pig and rat
    Patric Schyman, Richard L. Printz, Venkat Reddy Pannala, Mohamed Diwan M. AbdulHameed, Shanea K. Estes, Chiyo Shiota, Kelli Lynn Boyd, Masakazu Shiota, Anders Wallqvist · 2021 · Toxicology and Applied Pharmacology
47. The role of nuclear receptors in metabolic homeostasis and disease: From molecular mechanisms to drug discovery
    Fangfang He, Haomeng Wu, Feilong Zhao, Xinxin Liu, Qinbo Yang, Shiquan Zhou, Tao Xu, Jing Xu, Shuai Wang, Denglang Zou · 2025 · Pharmacological Research
48. Angelica dahurica extract and its effective component bergapten alleviated hepatic fibrosis by activating FXR signaling pathway
    Chong Gao, Zhong-He Hu, Zhenyu Cui, Yu-Chen Jiang, Jia-Yi Dou, Zhaoxu Li, Li‐Hua Lian, Ji‐Xing Nan, Yan‐Ling Wu · 2024 · Journal of Natural Medicines
49. New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
    Jinming Zhang, Yixin Li, Yang Liu, Ningning Ma, Shengying Qian, Yingfen Chen, Yajun Duan, Xiaogang Xiang, Yong He · 2024 · Cell & Bioscience
50. The treatment of primary biliary cholangitis: from shadow to light
    Sylvia Dražilová, Tomáš Koky, Marian Macej, Martin Janíčko, Dagmar Simkova, Peter Jarčuška · 2024 · Therapeutic Advances in Gastroenterology
51. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension
    Michał Porada, Łukasz Bułdak · 2025 · Metabolites
52. A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection
    Gaber El‐Saber Batiha, Hayder Mutter Al-Kuraishy, Ali Ismail Al-Gareeb, Fadia Salah Youssef, Suzy A. El-Sherbeni, Walaa A. Negm · 2022 · Inflammopharmacology
53. Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid
    Jaclynn A. Meshanni, Jordan M. Lee, Kinal N. Vayas, Rachel Sun, Chenghui Jiang, Grace Liejun Guo, Andrew J. Gow, Jeffrey D. Laskin, Debra L. Laskin · 2023 · Journal of Pharmacology and Experimental Therapeutics
54. New mechanistic insights into hepatoprotective activity of milk thistle and chicory quantified extract: The role of hepatic Farnesoid-X activated receptors.
    Azadeh Khalili, Parviz Fallah, Seyed Ali Hashemi, Mohammad Mahdi Ahmadian-Attari, Vahid Jamshidi, Roham Mazloom, Leila Beikzadeh, Gholamreza Bayat · 2021 · PubMed Central
55. Future Medical Treatment of PSC
    Elisabeth Krones, Hanns–Ulrich Marschall, Peter Fickert · 2019 · Current Hepatology Reports
56. Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis
    Lei Zou, Cuifen Shi, Dawei Wang, Juan Cheng, Qi Wang, Lei Wang, Guoya Yang · 2022 · Bioengineered
57. Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease
    Yongqiang Ma, Zhiyuan Tan, Qiang Li, Wenling Fan, Guangshun Chen, Yangyang Bin, Yi Zhou, Junfang Yi, Xiaohua Luo, Jieqiong Tan et al. · 2021 · Frontiers in Cell and Developmental Biology
58. Macrophage heterogeneity in liver fibrosis
    Wang, Wenzhao, Li, Shengwen, Liu, Yanjun, Ding, Xin, Yang, Yongqi, Chen, Shiyun, Cao, Jiafan, Tacke, Frank, Dong, Wei, Lan, Tian · 2025 · Frontiers in Immunology
59. Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
    Prakash Ramachandran, Madara Brice, Elena F. Sutherland, Anna M. Hoy, Eleni Papachristoforou, Jia Li, Frances S Turner, Timothy James Kendall, John A. Marwick, Neil O. Carragher et al. · 2024 · Hepatology Communications
60. Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis
    Jiahui Wang, Li Ma, Yuan An, Yan Ge, Dan Xu, Enqiang Mao · 2025 · Pharmaceuticals
61. FXR Friend-ChIPs in the Enterohepatic System
    Vik Meadows, Zhenning Yang, Veronia Basaly, Grace Liejun Guo · 2023 · Seminars in Liver Disease
62. The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis
    Zhe Ping Huang, Hye Kyoung Sung, Xingqun Yan, Shiyu He, Leigang Jin, Qin Wang, Xuerui Wu, Henry H. Hsu, Angelica Pignalosa, Kathryn S. Crawford et al. · 2024 · Clinical and Translational Science
63. Restoring FXR expression as a novel treatment strategy in liver cancer and other liver disorders
    Sosmitha Girisa, B. Aswani, M. Manickasamy, Mangala Hegde, M. Alqahtani, Mohamed Abbas, Gautam Sethi, A. Kunnumakkara · 2025 · Expert opinion on therapeutic targets
64. Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice
    Wencong Li, Suxian Zhao, Weiguang Ren, Yuguo Zhang, Rongqi Wang, Ling-Bo Kong, Qingshan Zhang, Yuemin Nan · 2021 · Experimental and Therapeutic Medicine
65. Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells
    Cristina Zivko, Finja Witt, Andreas Koeberle, Gregor Fuhrmann, Paola Luciani · 2022 · European Journal of Pharmaceutics and Biopharmaceutics
66. Challenges of in vitro modelling of liver fibrosis
    Patricia Ros-Tárraga, Estela Villanueva-Bádenas, Estela Sanchez-Gonzalez, Gloria Gallego Ferrer, María Teresa Donato, Laia Tolosa · 2025 · Frontiers in Cell and Developmental Biology
67. Unraveling functional dyspepsia: Pathophysiological mechanisms, microbiota interactions, and emerging therapeutic strategies
    Aisi Huang, Bixia Lin, Tao Hu, Jiao Xia Lan · 2025 · Pathology - Research and Practice
68. Modulation of immune responses by bile acid receptor agonists in myasthenia gravis
    Quentin Howlett-Prieto, Collin Langer, Kourosh Rezania, Betty C. Soliven · 2020 · Journal of Neuroimmunology
69. Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients
    Susu Feng, Si-Jing Wang, Lin Guo, Pan-Pan Ma, Xiaolong Ye, Minglin Pan, Bo Hang, Jian‐Hua Mao, Antoine M. Snijders, Yibing Lu et al. · 2024 · World Journal of Diabetes
70. Novel Therapies in Primary Biliary Cholangitis
    Keri-Ann Buchanan-Peart, Cynthia Levy · 2022 · Clinics in Liver Disease
71. Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in MAFLD and COVID-19 Outcomes
    Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Ivanivna Kamyshna, Ihor Vorobets, Oleksandr Kamyshnyi · 2024 · Preprints.org
72. New Insights on the potential therapeutic effects of glibenclamide and Obeticholic acid against Alloxan-Induced diabetes mellitus in rat model
    Asmaa Ali Aboushouk, ‏Hebatallah M. Saad, Aya H. Rohiem, Dina R. S. Gad El-Karim · 2024 · International Immunopharmacology
73. Chronic activation of FXR-induced liver growth with tissue-specific targeting Cyclin D1
    Weibin Wu, Qing Wu, Xin-Mei Liu · 2019 · Cell Cycle
74. Nanotherapy targeting liver sinusoidal endothelial cells in liver fibrosis
    Lingfeng Zhang, Jia-Wen Ru, Su-Qing Liang, Meng-Meng Zhang, Chun-Yu Zhang, Jia-Qi Liu, Yi Wang, Tian‐Jiao Zhou, Xian Wu Cheng, Lei Xing et al. · 2026 · Journal of Controlled Release
75. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT ‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial
    Thomas A. Capozza, Jennifer Burkey, Jeroen Van De Wetering, Reinhold Kerb, Jennifer Callahan, Ludmila A. Kryzhanovskaya, Mary Erickson · 2025 · Clinical and Translational Science
76. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease
    Lampros Chrysavgis, Ilias Giannakodimos, A. Chatzigeorgiou, K. Tziomalos, G. Papatheodoridis, E. Cholongitas · 2022 · Expert Review of Gastroenterology & Hepatology
77. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
    Beata Kasztelan‐Szczerbińska, Anna Rycyk, Agnieszka Szczerbińska, Halina Cichoż‐Lach · 2023 · Nutrients
78. Evolving insights in the pathophysiology of complications of cirrhosis: The farnesoid X receptor (FXR) to the rescue?
    W. Laleman, J. Trebicka, L. Verbeke · 2016 · Hepatology
79. Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70−/− Mice with a Human-like Bile Acid Composition
    Anna Palmiotti, Hilde D. de Vries, Milaine V. Hovingh, Martijn Koehorst, Niels L. Mulder, Esther Verkade, Melany K. Veentjer, Theo H. van Dijk, Vincent W. Bloks, Rick Havinga et al. · 2023 · Biomedicines
80. The gene regulatory networks shaping macrophage plasticity and altered function in fibrosis
    Zsuzsanna Kolostyák, László Nagy · 2026 · Frontiers in Immunology
81. Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis
    Dmitry Victorovich Garbuzenko · 2023 · World Journal of Hepatology
82. Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques
    Michael J. Nash, Evgenia Dobrinskikh, Saif I. Al‐Juboori, Rachel C. Janssen, Jolyn Fernandes, Amy Argabright, Angelo D’Alessandro, Melissa Ann Kirigiti, Paul Kievit, Kjersti Marie Aagaard et al. · 2025 · Liver International
83. The effect of compound DM509 on kidney fibrosis in the conditions of the experimental model
    Anna Stavniichuk, О. Savchuk, Abdul H. Khan, Wojciech K. Jankiewicz, John D. Imig, Daniel Merk · 2020 · Bulletin of Taras Shevchenko National University of Kyiv Series “Psychology”
84. Biliary cirrhosis-induced cardiac abnormality in rats: Interaction between Farnesoid-X-activated receptors and the cardiac uncoupling proteins 2 and 3.
    Gholamreza Bayat, Seyed Ali Hashemi, Hossein Karim, Parviz Fallah, Keshvad Hedayatyanfard, Mahnaz Bayat, Azadeh Khalili · 2022 · PubMed Central
85. ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model
    Eun Jeoung Lee, Yun Kim, Jieun Kim, Eileen Laureal Yoon, Sung Ryol Lee, Dae Won Jun · 2022 · Life
86. Occurrence, diagnosis and management of hepatic fibrosis and cirrhosis: An updated literature review
    Jing Qiao · 2019 · Archives of Hepatitis Research
87. Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential
    Dmitry Victorovich Garbuzenko · 2022 · Russian Journal of Evidence-Based Gastroenterology
88. Novel Targets and Drug Development in Portal Hypertension
    Robert Schierwagen, Sabine Klein, Frank Erhard Uschner, Jonel Trebicka · 2019 · Current Hepatology Reports
89. Hesperetin alleviates high-fat diet-induced NAFLD by activating FXR to modulate ferroptosis homeostasis and suppress inflammation
    Suwen Chen, Jin Xie, Guoliang Yin, Linya Wang, Yuzhi Jia, Hui Zhang, Yuehan Ren, Lijiang Ren, Qingyong He · 2026 · The Journal of Nutritional Biochemistry
90. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets
    Poonam Sahu, Trilochan Satapathy · 2026 · Probiotics and Antimicrobial Proteins
91. Discovery of Fluorescent Probe ABDS-2 for Farnesoid X Receptor Modulator Characterization and Cell-Based Imaging
    Xianjie Qiu, Wenqi Li, Xiaoqin Li, Bin Wu, Minxian Dai, Yi Xia, Gong Zhang, Yizhou Bian, Jiayi Chen, Kunzhong Wu et al. · 2025 · Analytical Chemistry
92. Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC
    Amit Kumar Ram, Gavin A. K. Wright, Balasubramaniyan Vairappan · 2019 · IntechOpen eBooks
93. Pharmacological management of portal hypertension and its complications in children: lessons from adults and opportunities for the future
    Sarah A.F. Henkel, Carol G. Vetterly, Robert H. Squires, Patrick James McKiernan, James E. Squires · 2020 · Expert Opinion on Pharmacotherapy
94. Advances in the treatment of nonalcoholic steatohepatitis
    Sandeep Mukherjee · 2020 · World Journal of Pharmacology
95. Saffron offers hepatoprotection via up-regulation of hepatic farnesoid-X-activated receptors in a rat model of acetaminophen-induced hepatotoxicity
    V. Jamshidi, S. Hashemi, A. Khalili, P. Fallah, M. Ahmadian-Attari, Leila Beikzadeh, R. Mazloom, P. Najafizadeh, G. Bayat · 2021 · Avicenna Journal of Phytomedicine
96. Generation and Culture of Primary Mouse Hepatocyte–Hepatic Stellate Cell Spheroids
    Inge Mannaerts, Nathalie Eysackers, Leo A. van Grunsven · 2023 · Methods in molecular biology
97. The Gut-Liver Axis in NAFLD Progression: Insights into Pathogenesis and Therapeutic Opportunities
    Kartik Dubey, Rachana Singh · 2024 · International Journal of Advanced Research in Science Communication and Technology
98. Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
    Elisabeth Tatscher, Samy Mady, Peter Fickert · 2025 · Seminars in Liver Disease
99. Obeticholic Acid and Methyl Ferulic Acid Mitigate Arsenic Trioxide‐Induced Hepatotoxicity by Targeting Profibrotic and Proinflammatory Signaling
    Souty M.Z. Sharkawi, Elshaimaa A Arafa, Ehab A. M. El‐Shoura, Rania A. Gad, Hany H. Arab, Marwa Mahmoud Khalaf · 2026 · Journal of Biochemical and Molecular Toxicology
100. Research progress on the role of gut microbiota dysbiosis in the pathogenesis of immune−mediated liver diseases
     Yang Chen, Zhenglian Wang, Yixuan Zeng, Xuqiu Xie, Linquan Liu, Yan Qian · 2026 · Frontiers in Immunology